The FDA on Tuesday approved Novartis' generic version of Teva Pharmaceutical's best-selling multiple sclerosis drug, Copaxone, reports Reuters.
Here are three things to know.
1. Glatopa, manufactured by Novartis' subsidiary Sandoz, is intended for patients with relapsing forms of multiple sclerosis. The drug is administered as an injection three times a week.
2. Sandoz earned FDA approval for a smaller dosage of Glatopa in 2015. Contamination issues at a production plant delayed regulatory approval of the new dosage form until this month.
3. Glatopa represents the second generic version of Teva's brand-name drug to enter the market. Mylan launched its version in 2017.